ketorolac ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibufenac derivatives 1529 74103-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketorolac
  • ketorolac tromethamine
  • ketorolac trometamol
  • trometamol ketorolac
  • (+/-)-Ketorolac
  • keromin
A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.
  • Molecular weight: 255.27
  • Formula: C15H13NO3
  • CLOGP: 1.62
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 59.30
  • ALOGS: -2.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 200 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 58 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.79 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.35 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 30, 1989 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 482.93 13.65 452 13073 250558 50341041
Punctate keratitis 88.07 13.65 22 13503 535 50591064
Corneal epithelium defect 77.57 13.65 18 13507 317 50591282
Spinal epidural haematoma 75.56 13.65 22 13503 967 50590632
Skin papilloma 69.52 13.65 30 13495 4199 50587400
Tendon disorder 62.92 13.65 30 13495 5292 50586307
Eye irritation 57.93 13.65 43 13482 17097 50574502
Renal infarct 52.62 13.65 18 13507 1342 50590257
Eye pain 51.84 13.65 50 13475 28399 50563200
Anterior chamber cell 51.43 13.65 14 13511 480 50591119
Injury 50.81 13.65 64 13461 48861 50542738
Retinal pigment epitheliopathy 48.69 13.65 11 13514 171 50591428
Corneal oedema 48.42 13.65 17 13508 1370 50590229
Aspirin-exacerbated respiratory disease 47.68 13.65 15 13510 859 50590740
Concussion 44.82 13.65 27 13498 7601 50583998
Ulcerative keratitis 43.16 13.65 18 13507 2315 50589284
Treatment failure 42.09 13.65 105 13420 137532 50454067
Purpura fulminans 41.72 13.65 8 13517 52 50591547
Meniscus injury 36.23 13.65 22 13503 6280 50585319
Uterine perforation 35.87 13.65 22 13503 6393 50585206
Corneal disorder 35.06 13.65 14 13511 1612 50589987
Anaphylactic reaction 34.38 13.65 56 13469 53999 50537600
Migraine 33.80 13.65 67 13458 75213 50516386
Respiratory tract infection viral 33.61 13.65 14 13511 1795 50589804
Musculoskeletal disorder 32.56 13.65 31 13494 17318 50574281
Emotional distress 32.17 13.65 39 13486 28624 50562975
Ocular hyperaemia 28.49 13.65 31 13494 20261 50571338
Visual acuity reduced 26.95 13.65 30 13495 20109 50571490
Sleep disorder 26.94 13.65 52 13473 57231 50534368
Vision blurred 26.15 13.65 62 13463 78585 50513014
Asymptomatic bacteriuria 25.23 13.65 7 13518 258 50591341
Myelomalacia 25.16 13.65 5 13520 40 50591559
Post-traumatic stress disorder 24.68 13.65 15 13510 4288 50587311
Systemic lupus erythematosus 24.66 13.65 4 13521 140618 50450981
Foreign body sensation in eyes 23.85 13.65 11 13514 1800 50589799
Tracheal deviation 23.81 13.65 5 13520 54 50591545
Renal ischaemia 23.68 13.65 8 13517 574 50591025
Intraocular pressure increased 23.63 13.65 16 13509 5500 50586099
Condition aggravated 21.89 13.65 145 13380 296913 50294686
Fibrosis 21.33 13.65 13 13512 3734 50587865
Corneal thinning 20.85 13.65 5 13520 102 50591497
Phrenic nerve paralysis 20.76 13.65 5 13520 104 50591495
Corneal abrasion 20.61 13.65 8 13517 854 50590745
Dystonia 19.93 13.65 20 13505 11906 50579693
Immune thrombocytopenia 18.63 13.65 17 13508 9000 50582599
Torsade de pointes 18.24 13.65 19 13506 11816 50579783
Persistent corneal epithelial defect 18.07 13.65 3 13522 7 50591592
Corneal perforation 17.18 13.65 6 13519 476 50591123
Renal papillary necrosis 17.03 13.65 5 13520 226 50591373
Abdominal pain 16.60 13.65 114 13411 236114 50355485
Alopecia 16.48 13.65 25 13500 245022 50346577
Spinal cord compression 16.47 13.65 11 13514 3698 50587901
Anxiety 16.42 13.65 92 13433 177514 50414085
Atrophy 16.24 13.65 8 13517 1515 50590084
Colitis ischaemic 16.02 13.65 16 13509 9467 50582132
Eye pruritus 15.62 13.65 18 13507 12516 50579083
Sinusitis 15.54 13.65 88 13437 170470 50421129
Depression 15.50 13.65 86 13439 165337 50426262
Fascial infection 15.45 13.65 3 13522 21 50591578
Corneal opacity 15.39 13.65 6 13519 648 50590951
Corneal dystrophy 15.34 13.65 5 13520 321 50591278
Opisthotonus 15.29 13.65 5 13520 324 50591275
Paraplegia 15.23 13.65 9 13516 2445 50589154
Hand deformity 15.19 13.65 4 13521 100195 50491404
Small intestinal obstruction 15.07 13.65 20 13505 16048 50575551
Hypothyroidism 14.86 13.65 30 13495 34095 50557504
Photophobia 14.69 13.65 19 13506 14868 50576731
Intervertebral discitis 14.57 13.65 9 13516 2647 50588952
Laryngeal dyspnoea 14.35 13.65 4 13521 150 50591449
Embedded device 14.03 13.65 9 13516 2828 50588771
Synovitis 13.77 13.65 8 13517 123857 50467742

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Victim of child abuse 123.63 17.48 30 6291 815 29567391
Respiratory depression 98.47 17.48 51 6270 13472 29554734
Drug hypersensitivity 96.04 17.48 94 6227 68312 29499894
Drug dependence 92.62 17.48 57 6264 20924 29547282
Treatment failure 86.61 17.48 68 6253 36871 29531335
Product prescribing error 72.18 17.48 46 6275 17930 29550276
Nightmare 68.87 17.48 38 6283 11379 29556827
Sedation 68.55 17.48 44 6277 17361 29550845
Epidural lipomatosis 63.37 17.48 17 6304 694 29567512
Nephrolithiasis 55.83 17.48 45 6276 25289 29542917
Juvenile idiopathic arthritis 52.07 17.48 17 6304 1377 29566829
Ulcerative keratitis 51.73 17.48 17 6304 1406 29566800
Anaphylactic reaction 48.46 17.48 43 6278 27530 29540676
Cataract 41.53 17.48 36 6285 22342 29545864
Asthma-chronic obstructive pulmonary disease overlap syndrome 35.79 17.48 11 6310 732 29567474
Burning feet syndrome 34.46 17.48 7 6314 81 29568125
Drug ineffective 30.30 17.48 155 6166 363015 29205191
Hyperhidrosis 29.59 17.48 51 6270 64489 29503717
Periorbital swelling 29.24 17.48 8 6313 352 29567854
Bronchial hyperreactivity 28.91 17.48 11 6310 1395 29566811
Intentional product misuse 28.39 17.48 36 6285 34625 29533581
Corneal thinning 26.01 17.48 6 6315 130 29568076
Obesity 24.91 17.48 19 6302 9844 29558362
Pulmonary function test abnormal 24.74 17.48 11 6310 2071 29566135
Child abuse 22.85 17.48 6 6315 225 29567981
Eye pain 22.20 17.48 19 6302 11576 29556630
Drug abuse 20.88 17.48 50 6271 79833 29488373
Non-infectious endophthalmitis 20.45 17.48 5 6316 140 29568066
Product used for unknown indication 20.19 17.48 6 6315 356 29567850
Corneal oedema 20.17 17.48 8 6313 1134 29567072
Aspirin-exacerbated respiratory disease 20.12 17.48 6 6315 360 29567846
Angioedema 19.83 17.48 29 6292 31886 29536320
Nausea 19.70 17.48 117 6204 289138 29279068
Urine analysis abnormal 19.67 17.48 9 6312 1811 29566395
Blood chromogranin A increased 18.78 17.48 5 6316 198 29568008
Neuromuscular block prolonged 18.73 17.48 6 6315 457 29567749
Urticaria 18.56 17.48 38 6283 54622 29513584
Eye swelling 18.26 17.48 15 6306 8642 29559564
Carcinoid crisis 18.01 17.48 5 6316 232 29567974

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 374.04 12.88 376 16056 237439 64244861
Victim of child abuse 117.45 12.88 30 16402 841 64481459
Respiratory depression 105.93 12.88 69 16363 23374 64458926
Punctate keratitis 103.07 12.88 27 16405 838 64481462
Corneal epithelium defect 79.78 12.88 21 16411 664 64481636
Spinal epidural haematoma 71.65 12.88 22 16410 1220 64481080
Anaphylactic reaction 68.60 12.88 86 16346 68578 64413722
Tendon disorder 68.25 12.88 33 16399 6299 64476001
Skin papilloma 64.93 12.88 30 16402 5173 64477127
Eye pain 64.62 12.88 58 16374 31567 64450733
Drug dependence 62.03 12.88 58 16374 33254 64449046
Nightmare 58.39 12.88 46 16386 20947 64461353
Anterior chamber cell 57.92 12.88 17 16415 807 64481493
Epidural lipomatosis 56.87 12.88 17 16415 860 64481440
Corneal oedema 54.38 12.88 21 16411 2322 64479978
Ulcerative keratitis 52.02 12.88 22 16410 3075 64479225
Injury 49.45 12.88 66 16366 55926 64426374
Aspirin-exacerbated respiratory disease 48.17 12.88 16 16416 1144 64481156
Nephrolithiasis 47.30 12.88 57 16375 43626 64438674
Renal infarct 43.42 12.88 18 16414 2393 64479907
Foreign body sensation in eyes 41.75 12.88 16 16416 1733 64480567
Uterine perforation 38.83 12.88 22 16410 5798 64476502
Eye irritation 38.29 12.88 32 16400 15824 64466476
Vision blurred 35.53 12.88 74 16358 90242 64392058
Product prescribing error 34.92 12.88 44 16388 35225 64447075
Sedation 33.76 12.88 47 16385 41415 64440885
Sleep disorder 33.56 12.88 57 16375 59652 64422648
Asthma-chronic obstructive pulmonary disease overlap syndrome 33.11 12.88 12 16420 1113 64481187
Juvenile idiopathic arthritis 32.36 12.88 17 16415 3862 64478438
Visual acuity reduced 32.00 12.88 37 16395 27104 64455196
Burning feet syndrome 30.51 12.88 7 16425 123 64482177
Ocular hyperaemia 30.44 12.88 33 16399 22531 64459769
Respiratory tract infection viral 29.37 12.88 14 16418 2589 64479711
Musculoskeletal disorder 29.22 12.88 29 16403 17877 64464423
Migraine 29.04 12.88 55 16377 62622 64419678
Corneal thinning 28.89 12.88 7 16425 157 64482143
Purpura fulminans 28.48 12.88 7 16425 167 64482133
Corneal opacity 27.93 12.88 10 16422 895 64481405
Concussion 27.86 12.88 20 16412 7918 64474382
Bronchial hyperreactivity 26.79 12.88 13 16419 2499 64479801
Emotional distress 26.62 12.88 39 16393 35999 64446301
Drug ineffective 26.00 12.88 327 16105 839920 63642380
Meniscus injury 25.73 12.88 17 16415 5890 64476410
Corneal abrasion 23.81 12.88 9 16423 939 64481361
Corneal disorder 23.17 12.88 11 16421 2016 64480284
Tracheal deviation 23.06 12.88 5 16427 67 64482233
Post-traumatic stress disorder 23.06 12.88 14 16418 4191 64478109
Intraocular pressure increased 22.67 12.88 18 16414 8284 64474016
Angioedema 22.40 12.88 49 16383 61772 64420528
Child abuse 22.10 12.88 6 16426 214 64482086
Immune thrombocytopenia 22.03 12.88 23 16409 15043 64467257
Urticaria 21.27 12.88 84 16348 147233 64335067
Pulmonary function test abnormal 21.22 12.88 12 16420 3152 64479148
Illness 21.13 12.88 27 16405 21911 64460389
Myelomalacia 20.20 12.88 5 16427 123 64482177
Death 20.04 12.88 60 16372 482645 63999655
Renal ischaemia 19.22 12.88 8 16424 1075 64481225
Phrenic nerve paralysis 17.34 12.88 5 16427 223 64482077
Drug abuse 17.15 12.88 73 16359 132301 64349999
Hyperhidrosis 17.05 12.88 70 16362 124850 64357450
Sinusitis 17.03 12.88 78 16354 145850 64336450
Ischaemic cardiomyopathy 16.92 12.88 14 16418 6824 64475476
Neuromuscular block prolonged 16.61 12.88 7 16425 970 64481330
Procedural pain 16.40 12.88 20 16412 15488 64466812
Eye swelling 16.29 12.88 24 16408 22257 64460043
Photophobia 16.21 12.88 21 16411 17272 64465028
Non-infectious endophthalmitis 15.90 12.88 5 16427 300 64482000
Condition aggravated 15.58 12.88 154 16278 372272 64110028
Asymptomatic bacteriuria 15.57 12.88 5 16427 321 64481979
Interstitial lung disease 15.57 12.88 3 16429 97729 64384571
Sickle cell anaemia with crisis 15.51 12.88 12 16420 5320 64476980
Corneal perforation 15.41 12.88 6 16426 678 64481622
Renal papillary necrosis 15.03 12.88 5 16427 359 64481941
Periorbital swelling 15.02 12.88 8 16424 1868 64480432
Abdominal pain 14.97 12.88 133 16299 312242 64170058
Heparin-induced thrombocytopenia test positive 14.97 12.88 4 16428 134 64482166
Blood chromogranin A increased 14.76 12.88 5 16427 380 64481920
Embedded device 14.67 12.88 9 16423 2743 64479557
Torsade de pointes 14.61 12.88 20 16412 17343 64464957
Fibrosis 14.54 12.88 11 16421 4717 64477583
Eye pruritus 14.49 12.88 17 16415 12642 64469658
Product used for unknown indication 14.29 12.88 6 16426 824 64481476
Anxiety 14.01 12.88 94 16338 202555 64279745
Carcinoid crisis 13.95 12.88 5 16427 449 64481851
Diarrhoea 13.31 12.88 119 16313 722585 63759715
Persistent corneal epithelial defect 13.22 12.88 3 16429 50 64482250
Lower respiratory tract infection 12.93 12.88 4 16428 94610 64387690

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01AB15 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Acetic acid derivatives and related substances
ATC S01BC05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Antiinflammatory agents, non-steroids
ATC S01FB51 SENSORY ORGANS
OPHTHALMOLOGICALS
MYDRIATICS AND CYCLOPLEGICS
Sympathomimetics excl. antiglaucoma preparations
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory agent
CHEBI has role CHEBI:50629 COX-2 inhibitor
CHEBI has role CHEBI:50630 COX-1 inhibitor
MeSH PA D000700 Analgesics
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
FDA EPC N0000175939 Cyclooxygenase Inhibitor
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Severe pain indication 76948002
Allergic conjunctivitis indication 473460002 DOID:11204
Acute postoperative pain indication 107401000119105
Postoperative Ocular Pain indication
Post-Op Ocular Inflammation indication
Post-Op Photophobia indication
Renal colic off-label use 7093002
Peptic ulcer contraindication 13200003 DOID:750
Disorder of cornea contraindication 15250008 DOID:10124
Acute gastric ulcer with perforation contraindication 19850005
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Tear film insufficiency contraindication 46152009
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Corneal erosion contraindication 50792001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Rheumatoid arthritis contraindication 69896004 DOID:7148
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Hemophilia contraindication 90935002
Corneal degeneration contraindication 111521006 DOID:1237
Perioperative care contraindication 133897009
Asthma contraindication 195967001 DOID:2841
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002
Preoperative Pain Management contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.47 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.3% BASE;EQ 1% BASE OMIDRIA RAYNER SURGICAL N205388 May 30, 2014 RX SOLUTION IRRIGATION 8173707 July 30, 2023 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
EQ 0.3% BASE;EQ 1% BASE OMIDRIA RAYNER SURGICAL N205388 May 30, 2014 RX SOLUTION IRRIGATION 9278101 July 30, 2023 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8207215 May 28, 2024 A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8377982 May 28, 2024 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8541463 May 28, 2024 A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8906950 May 28, 2024 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8946281 May 28, 2024 A METHOD OF TREATING OCULAR PAIN
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 9216167 May 28, 2024 A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
0.4% ACULAR LS ALLERGAN N021528 May 30, 2003 RX SOLUTION/DROPS OPHTHALMIC 8008338 May 24, 2027 A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.90 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 9.72 WOMBAT-PK CHEMBL
Serine/threonine-protein kinase PAK 1 Kinase IC50 4.44 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 4.94 CHEMBL
Aldose reductase Enzyme IC50 5.21 DRUG MATRIX
Prostaglandin-H2 D-isomerase Enzyme IC50 6.64 CHEMBL

External reference:

IDSource
4028637 VUID
N0000178380 NUI
D00813 KEGG_DRUG
74103-07-4 SECONDARY_CAS_RN
4019510 VANDF
4028637 VANDF
C0073631 UMLSCUI
CHEBI:6129 CHEBI
KTR PDB_CHEM_ID
CHEMBL469 ChEMBL_ID
CHEMBL1201124 ChEMBL_ID
DB00465 DRUGBANK_ID
D020910 MESH_DESCRIPTOR_UI
3826 PUBCHEM_CID
6661 IUPHAR_LIGAND_ID
5558 INN_ID
YZI5105V0L UNII
28200 RXNORM
30341 MMSL
39892 MMSL
4947 MMSL
9780 MMSL
d00273 MMSL
003539 NDDF
004812 NDDF
108512006 SNOMEDCT_US
108513001 SNOMEDCT_US
372501008 SNOMEDCT_US
D020911 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acular HUMAN PRESCRIPTION DRUG LABEL 1 0023-2181 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 23 sections
ACUVAIL HUMAN PRESCRIPTION DRUG LABEL 1 0023-3507 SOLUTION/ DROPS 4.50 mg OPHTHALMIC NDA 23 sections
ACULAR LS HUMAN PRESCRIPTION DRUG LABEL 1 0023-9277 SOLUTION/ DROPS 4 mg OPHTHALMIC NDA 22 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0093-0314 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0093-0314 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0069 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0072 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0076 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 27 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1134 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9883 INJECTION, SOLUTION 30 mg INTRAVENOUS ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9884 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 14 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9952 INJECTION, SOLUTION 15 mg INTRAVENOUS ANDA 14 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3793 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3793 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3795 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3795 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3796 INJECTION, SOLUTION 60 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3796 INJECTION, SOLUTION 60 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0487-6232 INJECTION 30 mg INTRAMUSCULAR ANDA 16 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6041 INJECTION 15 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6042 INJECTION 30 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6043 INJECTION 30 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 10544-222 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 12634-809 TABLET 10 mg ORAL ANDA 13 sections
ACULAR HUMAN PRESCRIPTION DRUG LABEL 1 16590-002 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 20 sections
KETOROLAC HUMAN PRESCRIPTION DRUG LABEL 1 16590-138 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-376 SOLUTION 5 mg OPHTHALMIC ANDA 18 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-207 SOLUTION/ DROPS 4.50 mg OPHTHALMIC ANDA 24 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-208 SOLUTION 4 mg OPHTHALMIC ANDA 22 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-209 SOLUTION 5 mg OPHTHALMIC ANDA 25 sections